Straits Times Index
3,174.63 -13.03 (-0.41%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,232.18 -153.69 (-0.94%) FTSE 100
7,877.05 0.00 (0.00%) Bitcoin USD
64,748.60 +3,635.20 (+5.95%) CMC Crypto 200
1,314.89 +2.27 (+0.17%)
Novo Nordisk A/S (0TDD.L)
| Previous close | 124.03 |
| Open | 122.58 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 119.91 - 122.58 |
| 52-week range | 68.37 - 142.93 |
| Volume | |
| Avg. volume | 22,405 |
| Market cap | 2.727B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 0.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.
- Zacks
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
- Zacks
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.
